Published 16 April 2018
Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.
The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in its product development pipeline.
The terminated programs were evaluating three synthetic endocannabinoid compounds, KAL436, KAL439 and KAL671, in bone fracture healing, and osteogenesis imperfecta and osteoporosis.
In connection with the termination of these programs, Kalytera has terminated its License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (“Yissum”), under which Kalytera had licensed rights to KAL436, KAL439 and KAL671.
Kalytera president and CEO Robert Farrell said: “The decision to terminate these programs is part of our overall strategy to